Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane

Patent 6238647 Issued on May 29, 2001. Estimated Expiration Date:

November 2, 2019. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

2868691

2885427

3014844

3219533

3261748

3320125

3809294

3897779

Steroidal aerosol compositions and process for the preparation thereof
Patent #: 4044126
Issued on: 08/23/1977
Inventor: Cook, et al.

Aerosol propellant compositions
Patent #: 4174295
Issued on: 11/13/1979
Inventor: Bargigia , et al.

More ...

Inventors

Assignee

Glaxo Group Limited

Application

No. 09/431872 filed on 11/02/1999

US Classes:

424/45Organic pressurized fluid

Examiners

Primary: Bawa, Raj

Attorney, Agent or Firm

Bacon & Thomas

International Classes

A61K 31/137 (20060101)
A61K 31/138 (20060101)
A61K 45/06 (20060101)
A61K 31/167 (20060101)
A61K 31/56 (20060101)
A61K 31/573 (20060101)
A61K 31/522 (20060101)
A61K 31/48 (20060101)
A61K 31/4523 (20060101)
A61K 45/00 (20060101)
A61K 31/135 (20060101)
A61K 9/12 (20060101)
A61K 31/352 (20060101)
A61K 31/44 (20060101)
A61K 31/4402 (20060101)
A61K 31/519 (20060101)
A61K 31/4738 (20060101)
A61K 31/4535 (20060101)
A61K 31/4458 (20060101)
A61K 31/4741 (20060101)
A61K 31/57 (20060101)

Foreign Application Priority Data

1991-12-12 GB

Abstract

This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.

Other References

Gennaro, A.R. (1985), Remington's Pharmaceutical Sciences (17^th Ed.), Mack Publication Co., pp. 1670-1677
Oberholz, Frankfurter Allgemeine Zeitung, Oct. 1989, vol. 25, No. 207, p. 7
Dalby et al., Pharmacetical Technology, Mar. 1990, vol. 14, No. 3, pp. 26-33
Amzacort™ carton, William H. Rorer, Inc., Fort Washington, Pennsylvania, USA 19034, 1986
Pharmaceutical Journal, Sep. 29, 1990, vol. 245, pp. 428-429
The Theory and Practice of Industrial Pharmacy, 2nd Ed., 1976, (Philadelphia, PA: Lea and Febiger), pp. 270 and 276-278
Handbook of Aerosol Technology, 2^nd Ed., 1979 (New York, New York: Van Nostrand Reinhold Company), pp. 30, 32, 33, 166, 167, 232, 233)
U.S. Senate Hearings, May 12-14, 1987, 343-347, (U.S. Government Printing Office, Washington, D.C., 1987), CIS: 1987-S321-26
Hagers Handbook of Pharmaceutical Practice, 1971, pp. 342-354 (Berlin: Springer-Verlag)